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Abstract
Purpose/Objective(s)—AXXXXX ZXXXX was a prospective trial evaluating the false 
negative rate of sentinel node (SLN) surgery after neoadjuvant chemotherapy (NAC) in breast 
cancer patients with initial node-positive disease. Radiation therapy (RT) decisions were at the 
discretion of treating physicians, providing an opportunity to evaluate variability in practice 
patterns following NAC.
Methods and Materials—Of 756 patients enrolled from July 2009 to June 2011, 685 met all 
eligibility requirements. Surgical approach, RT, ,and radiation field design were analyzed based 
on presenting clinical and pathologic factors.
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Results—Of 401 node-positive patients, mastectomy was performed in 148 (36.9%), 
mastectomy with immediate reconstruction in 107 (26.7%), and breast-conserving surgery (BCS) 
in 146 (36.4%). Of the 284 pathologically node-negative patients, mastectomy was performed in 
84 (29.6%), mastectomy with immediate reconstruction in 69 (24.3%) and BCS in 131 (46.1%).
Bilateral mastectomy rates were higher in women undergoing reconstruction compared to those 
without (66.5% vs 32.2%, p<0.0001). Usage of internal mammary RT was low (7.8%–11.2%) and 
did not differ between surgical approaches. Supraclavicular-RT rate ranged from 46.6% to 52.2% 
and did not differ between surgical approaches but was omitted in 193/408 (47.3%) of node-
positive patients. Rate of Axillary-RT was more frequent in patients who remained node-positive 
(p=0.002). However, 22% of patients who converted to node-negative still received Axillary RT. 
Post-mastectomy RT was more frequently omitted after reconstruction compared to mastectomy 
(23.9% vs 12.1%, p=0.002), and was omitted in 19 of 107 (17.8%) patients with residual node-
positive disease in the reconstruction group.
Conclusion—The majority of clinically node-positive patients treated with NAC undergoing 
mastectomy receive RT. RT was less common in patients undergoing reconstruction. There is 
wide variability in RT fields. These practice patterns conflict with expert recommendations and 
ongoing trial guidelines. There is a significant need for greater uniformity and guidelines 
regarding RT following NAC.
Keywords
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Introduction
Neoadjuvant chemotherapy (NAC) is commonly used in locally advanced and increasingly 
in the management of stage II breast cancer1–3. Randomized trials comparing NAC to 
standard adjuvant chemotherapy demonstrate similar overall survival and disease-free 
survival rates, but more patients were able to undergo BCS after NAC and a substantial 
proportion with complete clinical and pathologic responses4–6. The increased utilization of 
NAC can be attributed to a number of practical clinical advantages. Response to NAC is a 
powerful prognostic factor that can help the treating physicians evaluate tumor response and 
guide future systemic approaches and multimodality treatment recommendations7. 
Evaluation of response to NAC also provides an efficient approach for evaluating novel 
drugs in clinical trials8.
The increasing use of NAC has, however, introduced questions regarding appropriate local-
regional management, given that local-regional decision-making has traditionally been 
based on clinical and pathologic factors after upfront surgery3, 9, 10. With the broad range of 
responses to NAC, clinicians are faced with many decisions including appropriate imaging 
modalities in evaluating response, the optimal surgical approach to the breast, reliability of 
SLN surgery versus axillary lymph node dissection (ALND), the type and timing of 
reconstruction in anticipation of the need for radiation, and the appropriate use of regional 
nodal or post-mastectomy radiation (PMRT). Some of these issues are currently being 
addressed in ongoing randomized trials, such as NRG-9353/NSABPB-51/RTOG1304 
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(NRG_B-51) which is addressing the issue of potentially omitting regional nodal and PMRT 
in patients converting from node-positive to node-negative disease following NAC, and 
Alliance A011202, which is addressing whether axillary radiation alone is non-inferior to 
ALND in patients who remain SLN positive after NAC11–13.
American College of Surgeons Oncology Group (AXXXXX is now part of the Alliance for 
Clinical Trials in Oncology) ZXXXX was a phase II, multicenter trial enrolling patients with 
node-positive disease treated with NAC14 to determine the false negative rate of SLN 
surgery following NAC. All patients had biopsy proven node-positive breast cancer at 
diagnosis and then had SLN surgery followed by completion ALND after NAC. Since the 
primary endpoint of ZXXXX was solely to determine the false negative rate of SLN surgery, 
local-regional management (beyond the required ALND) was left to the discretion of the 
treating physicians. Decisions regarding BCS or mastectomy, reconstruction, subsequent 
systemic therapy and RT were based on standard practices as determined by the treating 
physicians, with no specific guidelines within the trial regarding RT indications or field 
design. ZXXXX therefore offers a unique opportunity to evaluate contemporary practice 
patterns of local-regional therapy after NAC to assess variability in practice to inform gaps 
in education and the need for practice guidelines.
The current study examined local-regional treatment after NAC in patients enrolled in 
ZXXXX, with specific attention to surgical approaches, use of reconstruction after 
mastectomy, and utilization of post-mastectomy and regional nodal irradiation, as a function 
of clinical factors, nodal status and response to NAC.
Methods and Materials
AXXXXX ZXXXX was approved by the institutional review boards of participating 
institutions and participants provided written informed consent. All patients had T0–T4, N1–
N2, M0 primary invasive breast cancer, ECOG performance status 0 or 1, and underwent 
NAC. Nodal metastasis at initial diagnosis was confirmed by fine needle aspirate or core 
biopsy. Surgery was performed within 84 days of completion of NAC, and all patients 
underwent appropriate treatment of the primary tumor by BCS, mastectomy, or mastectomy 
with immediate reconstruction, based on clinical judgement, patient and physician 
preference. All patients underwent SLN surgery followed by completion ALND. Further 
details of the trial with respect to the false negative rate of SLN have been previously 
published14. As noted above there were no specific guidelines or central review related to 
RT as the intent of the trial was limited to determining the false negative rate of the SLN 
surgery.
The records of patients enrolled in AXXXXX ZXXXX were reviewed with specific 
attention to local-regional management details following NAC. For the current analysis, 
surgical and radiation details as a function of clinical presentation, nodal status, and 
response to NAC were documented from the original case report forms in an effort to 
determine practice variability, needs for practice guidelines and potential issues for future 
trials.
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Statistical analysis
Categorical variables were summarized as frequencies and percentages. Comparisons of 
categorical variables between groups were made with a chi-square test or Fisher’s exact test 
if expected cell sizes were too small for the chi-square test. All tests were two-sided, and p-
values less than 0.05 were considered to be statistically significant. Data collection and 
statistical analyses were conducted by the Alliance Statistics and Data Center. Analyses 
were performed using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina) on a 
dataset frozen on March 13, 2013.
Results
A total of 756 women were enrolled in ZXXXX from July 2009 to June 2011, of whom 701 
met all eligibility requirements, underwent the mandated SLN surgery and completion 
ALND. Nodal status following NAC was not documented in one patient, and surgical details 
were not available in 15 patients, leaving 685 patients eligible for the current analysis.
Clinical characteristics of patients in the trial by surgical management of the primary tumor 
are summarized in Table 1. All patients who underwent immediate reconstruction or an 
expander for subsequent reconstruction were classified as mastectomy with immediate 
reconstruction.
Local-regional management (breast surgical procedure and radiation fields) following NAC 
for the 685 patients is summarized in Figures 1A (node-positive following NAC) and 1B 
(node-negative following NAC). Of the 685 patients, 401 (58.5%) remained node-positive 
following chemotherapy, and 284 (41.5%) converted to node-negative.
Surgical approach
Of the 401 node-positive patients, mastectomy was performed in 148 (36.9%), mastectomy 
with immediate reconstruction in 107 (26.7%), and BCS in 146 (36.4%). Of the 284 node-
negative patients, mastectomy was performed in 84 (29.6%), mastectomy with immediate 
reconstruction in 69 (24.3%) and BCS in 131 (46.1%).
The rates of BCS were higher in patients with triple-negative and HER2-positive breast 
cancer, 79/170 (46.5%) and 89/212 (42.0%), respectively, compared to those patients with 
hormone-receptor-positive, HER2-negative disease (39.4%, p=0.024).
BCS was more commonly performed in those patients presenting with smaller primary 
tumors. with 82.7% of BCS cases having clinical stage cT0-cT2 disease at presentation. 
Patients undergoing BCS had higher rates of pathologic complete response in both the 
primary tumor (43.0% pathologically T0 or Tis) and nodes (47.3% pathologically node-
negative) compared to patients undergoing mastectomy with or without immediate 
reconstruction (p < 0.0001; see Table 1). RTwas omitted in 10.7% of patients after BCS.
Of the patients who underwent mastectomy, a higher portion undergoing immediate 
reconstruction presented with earlier clinical stages of disease (Table 2). Use of immediate 
reconstruction was higher in patients presenting with cT0-2 tumors than those with cT3-4 
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disease (p < 0.0001). However, there were no significant differences in the final pathologic 
T-stage or N-stage between the patients undergoing mastectomy without reconstruction 
compared with those having immediate reconstruction.
Bilateral mastectomy rates were significantly higher in women undergoing immediate 
reconstruction compared to women without immediate reconstruction (66.5% vs 32.2%, 
p<0.0001).
Radiation Approach
As demonstrated in Figure 1, whether nodes remained positive or converted to node-
negative after NAC, RT was employed in the vast majority of patients, regardless of the 
treatment of the primary tumor.
RT details are summarized in Tables 3–5. RT was more frequently used in patients 
undergoing mastectomy without reconstruction [204/232 (87.9%)] compared to patients 
undergoing mastectomy with reconstruction [134/176 (76.1%), p=0.002]. Of patients who 
remained node-positive following NAC, RT was employed in 133/148 (89.9%) of the 
mastectomy patients compared to 88/107 (82.2%) of the mastectomy with reconstruction 
patients (p=0.077). Although not statistically significant, PMRT was omitted more 
frequently in the mastectomy with reconstruction patients compared to the patients 
undergoing mastectomy without reconstruction, despite the fact that the final pathologic T-
stage and N-stage did not differ between these two groups.
In those patients converting to node-negative after NAC (Figure 1B), PMRT was employed 
in 71/84 (84.5%) of the mastectomy patients compared to 46/69 (66.7%) of those 
undergoing mastectomy with reconstruction (p< 0.001).
Although PMRT was omitted more frequently in patients undergoing reconstruction, the 
majority of mastectomy patients in both the node-negative (76%) and node-positive (87%) 
cohorts did receive PMRT.
For all surgical approaches, regional nodal irradiation in some form was employed in the 
majority of node-positive and node-negative patients.
Internal mammary radiation use was low, ranging from 7.8% to 11.2%, and did not differ by 
surgical approach, pathological tumor stage or nodal response. Similarly, rates of 
supraclavicular radiation ranged from 46.6% to 52.2% and did not differ between surgical 
approaches, pathological tumor stage or nodal response. Notably, supraclavicular radiation 
was omitted in 193/408 (47.3%) of patients with residual node-positive disease after NAC.
The use of axillary radiation was variable in this group of patients, all of whom underwent 
completion ALND. Axillary radiation was used more frequently in those patients remaining 
node-positive after NAC (p=0.002, Table 4) as well as those with residual disease in the 
breast (p=0.025). Axillary radiation was used less frequently in those undergoing BCS, 
consistent with the higher rate of pN0 patients in the BCS cohort. Of note, 22% (62/284) of 
patients who converted to pathologic node-negative disease and underwent completion 
ALND received axillary radiation.
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Discussion
The increasing use of NAC has significantly impacted local-regional decision-making for 
patients and their treating physicians.3, 9–12. Surgical decision-making in patients 
undergoing NAC is complex, and involves consideration of response to therapy, patient and 
clinician preferences, and clinical judgement.
As expected, BCS was more common among women with higher response rates to NAC15. 
However, a significant proportion of patients with a good response to NAC still elect to 
undergo mastectomy. The decision-making is multifactorial and may reflect factors at 
presentation despite a good response to NAC, and difficulties with interpretation of imaging 
modalities to evaluate extent of residual disease.15 Details on family history and genetic 
testing were not available for the current study population and could also have impacted 
decision-making.
Of those patients in ZXXXX undergoing mastectomy after NAC, 43% underwent immediate 
reconstruction. Bilateral mastectomy was more common in those women electing 
reconstruction. This is in keeping with previous studies that have reported immediate 
reconstruction is associated with higher rates of bilateral mastectomy for breast cancer16. 
This has been attributed to improved symmetry with bilateral reconstruction compared with 
unilateral reconstruction and a contralateral symmetrisation procedure17
The high rate of mastectomy with immediate reconstruction in this cohort of women who 
presented with node-positive disease demonstrates a paradigm shift from earlier time periods 
where immediate reconstruction was not favored if PMRT was anticipated. This may in part 
be due to increasing rates nationally of immediate reconstruction in women undergoing 
mastectomy for breast cancer.16
While patients undergoing mastectomy without reconstruction presented with higher stages 
of disease compared to the immediate reconstruction group, the post-treatment pathologic T 
and N stages of these two groups were similar. Although pathologic data would usually not 
be available until several days after the surgery, these data suggest that the initial clinical 
stage may still be an important driver in decision-making regarding immediate 
reconstruction rather than the response to therapy. This may also be a reflection of the fact 
that currently available imaging modalities cannot fully assess response to therapy, as 
reported in a previous analysis of ZXXXX15. Improvements in imaging and predictors of 
pathologic complete response could aid in patient counselling and decision-making. During 
the time of receiving NAC patients may also gain additional information regarding genetic 
testing results, reconstructive options and experiences of other breast cancer patients, all of 
which may influence individual treatment decisions.
Local-regional management practice patterns following NAC from patients enrolled in 
ZXXXX confirm a lack of uniformity with wide variations in practice, stressing the need for 
clinical trials, practice guidelines or consensus statements in this setting. Although NCCN 
guidelines do recommend PMRT following NAC for advanced breast cancer, more detailed 
practice statements and targeted education of the surgical, medical and radiation oncology 
community can serve to lower practice variability18. In addition, this variability highlights 
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the importance of detailed guidelines regarding radiation field design and dose constraints, 
with centralized review and quality assurance. Close collaboration of all members of the 
multidisciplinary team, including the radiation oncologist, is essential in patients with 
advanced breast cancer regardless of response to NAC.
Two ongoing trials may help address several unresolved issues. Both trials have similar 
radiation field design and dose constraint guidelines that can be helpful in driving more 
uniformity in the delivery of radiation. Even for patients ineligible or unwilling to 
participate in the trials, the RT guidelines and dose constraints provide a useful resource for 
local-regional treatment after NAC. Alliance A011202 will address whether axillary 
radiation is non-inferior to ALND following NAC. NRG_B-51 will determine the need for 
PMRT or regional nodal irradiation in patients who convert to node-negative after NAC12.
There are some clinical data suggesting that in women who experience a complete response 
with NAC, omission of PMRT or elimination of regional nodal irradiation after BCS and 
radiation may be an option10, 19–21. Therefore NRG_B-51 randomizes mastectomy patients 
who convert to node-negative after NAC to PMRT or no further radiation, and patients 
undergoing BCS to breast radiation only or breast and regional nodal irradiation. Our data 
confirm wide variability in practice, reflecting the need for this trial. Of patients treated with 
BCS who converted to node-negative, it is interesting that regional nodal irradiation was 
employed in just over 50% reflecting uncertainty of the appropriate approach to regional 
nodal irradiation in this setting of true equipoise supporting the need for a randomized trial. 
Over 70% of patients treated with mastectomy who converted to node-negative received 
PMRT in our cohort, suggesting that the current most commonly practiced standard is to 
perform PMRT even with complete response. However 24% omitted PMRT, indicating 
variability across practices. The ongoing NRG_B-51 has the potential to significantly 
change practice if it demonstrates equivalence in omission of radiation in this setting.
Our data also revealed variations in radiation field design, often conflicting with the current 
radiation guidelines in the NRG and Alliance trials and conflicting with NCCN 
recommendations18. Although our data were retrieved from the original case report forms as 
opposed to centralized film review, introducing some uncertainty regarding the delivered 
radiation volumes, a previous analysis of AXXXXX Z0011 fields demonstrated excellent 
concordance between the case data report forms and centralized film review22.
Despite persistent node-positive disease following NAC, among patients receiving RT, 
supraclavicular radiation was omitted in 47% of patients. The benefit of regional nodal 
irradiation has recently been demonstrated in two randomized trials in patients with early 
stage node-positive or high-risk node-negative disease following upfront surgery.23, 24 For 
patients with node-positive disease that persists even after NAC, the potential benefit may 
be greater and supraclavicular radiation is prudent and should be strongly recommended.
Internal mammary radiation was low in our cohort, reflecting a reluctance to recognize 
deliberate targeting of internal mammary nodes as a significant contribution to the benefits 
of regional nodal irradiation. Several trials have attempted to address this issue with 
conflicting reports, although most trials demonstrating an advantage to regional nodal 
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irradiation employed internal mammary radiation, including two recent trials published in 
patients with earlier stage disease23–25. Furthermore, the recent Danish DBCG-IMN 
prospective study demonstrated an advantage to internal mammary radiation26. While we 
cannot comment on the benefit of internal mammary radiation from our data, it is clear that 
its use is limited and additional justification and educational resources will be required to 
increase its utilization.
Management of the axilla in node-positive disease is complex, requiring close coordination 
among the multidisciplinary team27. The accuracy of SLN surgery and the false negative 
rate from the ZXXXX trial have been previously reported14. Whether axillary radiation can 
replace ALND in those patients who remain SLN positive is being addressed in Alliance 
A011202, which randomizes patients who are SLN positive following NAC to ALND plus 
radiation to the undissected Level II/III nodes, or full axillary and nodal radiation without 
further surgery13. The AMAROS trial demonstrated equivalent regional control in patients 
who underwent axillary radiation compared to ALND for the group of patients treated with 
upfront surgery who were SLN positive, with decreased morbidity associated with axillary 
radiation28. However, patients who remain SLN positive after NAC are a higher risk group 
and the Alliance A011202 trial will address whether axillary radiation can replace ALND in 
this setting12.
Variability in the use of axillary radiation after completion ALND is expected, and often 
depends on a number of factors including the extent of ALND, residual nodal burden, initial 
nodal status, physician biases and preferences, and clinical judgement3. However, in patients 
who undergo completion ALND, as was done in all patients in this cohort, axillary radiation 
should typically be employed selectively in patients with a heavy residual nodal burden or 
inadequate dissection. Both the NRG_B-51 and Alliance A011202 trials discourage axillary 
radiation in patients undergoing completion ALND, except in the circumstances of an 
inadequate sampling or heavy tumor burden. In the current series it is notable that 22% of 
patients with complete axillary response (pN0) and completion ALND also received axillary 
radiation. This also demonstrates a gap in knowledge and need for clinical practice 
guidelines.
Omission of radiation in patients undergoing immediate reconstruction also raises concerns. 
While it is expected that there is variability and lack of consensus regarding the need for 
PMRT, particularly in those patients converting to node-negative, it is generally accepted 
that patients with persistently node-positive disease after NAC should receive PMRT.9 
Furthermore, NRG_B-51excludes patients who remain node-positive after NAC as experts 
felt uncomfortable omitting radiation in this setting. Omission of PMRT in nearly 20% of 
patients with persistently node-positive disease in the current study also points to the need 
for education and guidance. It is interesting that PMRT was employed less frequently in 
reconstructed patients than in patients without reconstruction, despite the fact that there was 
no significant difference in the pathologic T or N stages between these groups, suggesting 
that immediate reconstruction and cosmetic issues may have influenced oncologic decision-
making. Prior consultation with radiation oncologists regarding the use of immediate 
reconstruction is recommended, so that the patient can be fully informed and the radiation 
oncologist can be involved with the multidisciplinary decision-making.
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In conclusion, results from AXXXXX ZXXXX demonstrate wide variability in local-
regional practice patterns following NAC in patients with initial node-positive disease. 
While ongoing trials will help to address several unanswered questions, there is a need for 
more uniformity, practice guidelines and education to fill gaps in knowledge and alter 
practice patterns. While controversies and uncertainties will remain with some necessary 
variation in practice, several areas that deserve attention include factors that drive oncologic 
decision-making in the setting of immediate reconstruction and appropriate radiation field 
selection and design after NAC.
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Summary
Local-regional management following neoadjuvant chemotherapy in ACOSOG 1071 
were reviewed. All patients had node positive breast cancer treated with neoadjuvant 
chemotherapy, sentinel node and completion axillary dissection. Review of the records 
revealed wide variability in practice, particularly regarding administration of radiation 
therapy, often conflicting with practice recommendations and guidelines. The study 
emphasizes the need for education, clinical practice statements and trials to address these 
issues and reduce variability in practice.
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Figure 1. 
Figure 1A. Local-regional management of node-positive patients following chemotherapy 
from AXXXXX ZXXXX
RNI, regional nodal irradiation; RT, radiation therapy
*Regional Nodal Irradiation
Figure 1B. Local-regional management of node-negative patients following chemotherapy 
from AXXXXX ZXXXX
RNI, regional nodal irradiation; RT, radiation therapy
*Regional Nodal Irradiation
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Table 2
Comparison of mastectomy patients (N = 408) with or without immediate reconstruction
Mastectomy without reconstruction Mastectomy with 
immediate 
reconstruction
p-value
Number of patients 232 (56.9%) 176 (43.1%)
Clinical tumor stage at presentation <0.0001
cT0/Tis 1 (0.4%) 3 (1.7%)
cT1 23 (9.9%) 28 (16.0%)
cT2 98 (42.2%) 94 (53.7%)
cT3 84 (36.2%) 48 (27.4%)
cT4 26 (11.2%) 2 (1.1%)
Unknown 0 1
Clinical nodal stage at presentation 0.93
cN1 214 (93.4%) 163 (93.7%)
cN2 15 (6.6%) 11 (6.3%)
Unknown 3 2
Clinical stage at presentation 0.0003
II 115 (50.2%) 118 (68.2%)
III 114 (49.8%) 55 (31.8%)
Unknown 3 3
Pathological tumor stage at surgery 0.71
pT0/is 59 (25.6%) 50 (28.7%)
pT1 85 (37.0%) 64 (36.8%)
pT2 50 (21.7%) 41 (23.6%)
pT3 34 (14.8%) 18 (10.3%)
pT4 2 (0.9%) 1 (0.6%)
Unknown 2 2
Pathological nodal stage at surgery 0.12
pN0 84 (36.2%) 69 (39.2%)
pN1 72 (31.0%) 63 (35.8%)
pN2 51 (22.0%) 36 (20.4%)
pN3 25 (10.8%) 8 (4.6%)
Unknown 0 0
Approximated tumor subtype 0.80
Triple negative 49 (21.1%) 40 (22.7%)
HER2 positive 70 (30.2%) 48 (27.3%)
HR positive, HER2 
negative
113 (48.7%) 88 (50.0%)
Unknown 0 0
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Mastectomy without reconstruction Mastectomy with 
immediate 
reconstruction
p-value
Laterality of surgery <0.0001
Unilateral 156 (67.8%) 59 (33.5%)
Bilateral 74 (32.2%) 117 (66.5%)
Unknown 2 0
Radiation therapy 0.002
Yes 204 (87.9%) 134 (76.1%)
No 28 (12.1%) 42 (23.9%)
Unknown 0 0
Radiation No Radiation p value
Pathological complete response Yes 64 (18.9%) 26 (37.1%) 0.0008
No 274 (81.1%) 44 (62.9%)
Unknown 0 0
Pathological T stage pT0/is 82 (24.6%) 27 (38.6%) <0.0001
pT1 123 (36.8%) 26 (37.1%)
pT2 80 (24.0%) 11 (15.7%)
pT3 49 (14.7%) 3 (4.3%)
pT4 0 3 (4.3%)
Unknown 4 0
Pathological N stage pN0 117 (34.6%) 36 (51.4%) 0.008
pN1-3 221 (65.4%) 34 (48.6%)
Unknown 0 0
Approximated tumor subtype 0.63
Triple negative 73 (21.6%) 16 (22.9%)
HER2 positive 95 (28.1%) 23 (32.9%)
HR positive, HER2 
negative
170 (50.3%) 31 (44.3%)
Unknown 0 0
HER2, human epidermal growth factor receptor 2; HR, hormone receptor
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Table 4
Axillary radiation
Axillary radiation received
Yes No p value
Type of breast surgery
Breast conserving surgery 64 (34.6%) 207 (41.9%) 0.12
Mastectomy without reconstruction 64 (34.6%) 168 (34.0%)
Mastectomy with reconstruction 57 (30.8%) 119 (24.1%)
Unknown 7 6
Clinical tumor stage at presentation
cT0/Tis 4 (2.1%) 6 (1.2%) 0.85
cT1 26 (13.5%) 63 (12.6%)
cT2 105 (54.7%) 274 (54.9%)
cT3 50 (26.0%) 131 (26.2%)
cT4 7 (3.6%) 25 (5.0%)
Unknown 0 1
Clinical nodal stage at presentation
cN1 179 (94.2%) 469 (94.4%) 0.94
cN2 11 (5.8%) 28 (5.6%)
Unknown 2 3
Clinical stage
II 127 (66.8%) 326 (65.7%) 0.78
III 63 (33.2%) 170 (34.3%)
Unknown 2 4
Pathological tumor stage at surgery
pT0/is 54 (28.6%) 176 (35.3%) 0.025
pT1 62 (32.8%) 187 (37.5%)
pT2 55 (29.1%) 93 (18.6%)
pT3 18 (9.5%) 40 (8.0%)
pT4 0 3 (0.6%)
Unknown 3 1
Pathological nodal stage at surgery
pN0 62 (32.3%) 222 (44.4%) 0.002
pN1 65 (33.8%) 174 (34.8%)
pN2 48 (25.0%) 81 (16.2%)
pN3 17 (8.8%) 23 (4.6%)
Unknown 0 0
Approximated tumor subtype
Triple negative 48 (25.0%) 120 (24.0%) 0.13
HER2 positive 48 (25.0%) 163 (32.6%)
HR positive, HER2 negative 96 (50.0%) 217 (43.4%)
Unknown 0 0
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HER2, human epidermal growth factor receptor 2; HR, hormone receptor
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Table 5
Supraclavicular radiation
Supraclavicular radiation received
Yes No p value
Type of breast surgery
Breast conserving surgery 134 (39.8%) 137 (39.9%) 0.54
Mastectomy without reconstruction 121 (35.9%) 111 (32.5%)
Mastectomy with reconstruction 82 (24.3%) 94 (27.4%)
Unknown 8 5
Clinical tumor stage at presentation
cT0/Tis 6 (1.7%) 4 (1.2%) 0.036
cT1 38 (11.0%) 51 (14.7%)
cT2 187 (54.4%) 192 (55.3%)
cT3 103 (29.9%) 78 (22.5%)
cT4 10 (2.9%) 22 (6.3%)
Unknown 1 0
Clinical nodal stage at presentation
cN1 319 (93.0%) 329 (95.6%) 0.14
cN2 24 (7.0%) 15 (4.4%)
Unknown 2 3
Clinical stage
II 217 (63.4%) 236 (68.6%) 0.15
III 125 (36.6%) 108 (31.4%)
Unknown 3 3
Pathological tumor stage at surgery
pT0/is 109 (32.0%) 121 (34.9%) 0.20
pT1 126 (37.0%) 123 (35.4%)
pT2 81 (23.8%) 67 (19.3%)
pT3 25 (7.3%) 33 (9.5%)
pT4 0 3 (0.9%)
Unknown 4 0
Pathological nodal stage at surgery
pN0 130 (37.7%) 154 (44.4%) 0.13
pN1 121 (35.1%) 118 (34.0%)
pN2 75 (21.7%) 54 (15.6%)
pN3 19 (5.5%) 21 (6.0%)
Unknown 0 0
Approximated tumor subtype
Triple negative 84 (24.4%) 84 (24.2%) 0.99
HER2 positive 105 (30.4%) 106 (30.6%)
HR positive, HER2 156 (45.2%) 157 (45.2%)
negative
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Supraclavicular radiation received
Yes No p value
Unknown 0 0
HER2, human epidermal growth factor receptor 2; HR, hormone receptor
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